07.07.20
Uzbekistan might start production of the new drug "Kuvipir" against coronavirus infection based Favipiravir. This was reported by the press service of the Agency for the development of the pharmaceutical industry of the Republic of Uzbekistan.
According to Shamshod Sharipov, Director of QualityControl of the pharmaceutical company Nobel Pharmsanoat, the patent for this drug belongs to the Japanese company Toyama Chemical.
"It has been proven that this drug has a wide spectrum of effects against viruses that involve RNA (influenza, rhinovirus, respiratory viruses, etc.), and has a positive anti-coronavirus effect. It has been used in Japan since February 2020 to treat patients with coronavirus. Starting from this month, the Chinese company Zhejiang Hisun Pharmaceutical started producing it under the trade name "Favilavir". In Russia, the production of drug "Avifavir" was launched in May by "KhimRam" and the Russian Investment Fund," – said Sharipov. It is noted that the drug "Kuvipir" will be in the first place produced for the needs of Uzbekistan.
